These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 37153833)

  • 1. Insights into the Oncogenic, Prognostic, and Immunological Role of BRIP1 in Pan-Cancer: A Comprehensive Data-Mining-Based Study.
    Liu Y; Wu X; Feng Y; Jiang Q; Zhang S; Wang Q; Yang A
    J Oncol; 2023; 2023():4104639. PubMed ID: 37153833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic pan-cancer analysis identifies cuproptosis-related gene DLAT as an immunological and prognostic biomarker.
    Xu L; Wu P; Rong A; Li K; Xiao X; Zhang Y; Wu H
    Aging (Albany NY); 2023 May; 15(10):4269-4287. PubMed ID: 37199628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimolecular characteristics and role of BRCA1 interacting protein C-terminal helicase 1 (BRIP1) in human tumors: a pan-cancer analysis.
    Wang R; Zhang J; Cui X; Wang S; Chen T; Niu Y; Du X; Kong J; Wang L; Jiang Y
    World J Surg Oncol; 2023 Mar; 21(1):91. PubMed ID: 36907870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
    Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
    Front Immunol; 2021; 12():812713. PubMed ID: 35069601
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
    Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
    [No Abstract]   [Full Text] [Related]  

  • 6. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 7. A comprehensive pan-cancer analysis identifies a novel glycolysis score and its hub genes as prognostic and immunological biomarkers.
    Zheng D; Long S; Xi M
    Transl Cancer Res; 2023 Oct; 12(10):2852-2874. PubMed ID: 37969385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Integrated Analysis Identified TAGLN2 As an Oncogene Indicator Related to Prognosis and Immunity in Pan-Cancer.
    Pan T; Wang S; Wang Z
    J Cancer; 2023; 14(10):1809-1836. PubMed ID: 37476180
    [No Abstract]   [Full Text] [Related]  

  • 10. ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis.
    Ning Y; Li Y; Wang H
    Front Genet; 2023; 14():1108167. PubMed ID: 36713082
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic Implication and Oncogenic Role of PNPO in Pan-Cancer.
    Zhang L; Li X; Zhang J; Xu G
    Front Cell Dev Biol; 2021; 9():763674. PubMed ID: 35127701
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
    Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
    Front Genet; 2022; 13():993438. PubMed ID: 36685895
    [No Abstract]   [Full Text] [Related]  

  • 13. Spectrum of BRCA1 interacting helicase 1 aberrations and potential prognostic and therapeutic implication: a pan cancer analysis.
    Long G; Hu K; Zhang X; Zhou L; Li J
    Sci Rep; 2023 Mar; 13(1):4435. PubMed ID: 36932143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
    Zhao C; Liu Y; Ju S; Wang X
    Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
    Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
    Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive pan-cancer analysis reveals prognostic implications of TMEM92 in the tumor immune microenvironment.
    Wu Z; Pan T; Li W; Zhang YH; Guo SH; Liu Y; Zhang L; Wang ZY
    Clin Transl Oncol; 2024 Oct; 26(10):2701-2717. PubMed ID: 38642258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
    Huang S; Dong C; Li D; Xu Y; Wu J
    Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic analysis of
    Jiang Y; Wang X; Li L; He J; Jin Q; Long D; Liu C; Zhou W; Liu K
    Front Genet; 2022; 13():926943. PubMed ID: 35991552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.